Skip to content

CallsBuy Calls Earnings

Check stock Discover Ask

My feed Smart money Buy Calls Check

Back to stock search

Save to watchlist

Immunovant Inc

IMVT•NASDAQ•HEALTHCAREMarket data unavailable

Price is syncing

Reported smart-money activity is still available below.

1 month

-0.1%

price return

Year to date

-7.0%

price return

Recent earnings

2/4

quarters beat

Big funds

8

hold this stock

News tone

Bearish

10 articles, 7 days

Smart money

Filed positions and reported activity tied to this stock.

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

8 funds hold a position and insiders have been net selling.

Real smart money

Funds holding this stock

8 holders

Combined position$688.3M

P
Point72
Steven Cohen · Q4 2025 13F
$50.8M
position
FC
Farallon Capital Management LLC
Q1 2026 13F
$38.4M
position
JS
Jim Simons
Q1 2026 13F
$4.8M
position
MW
Marshall Wace
Q1 2026 13F
$4.1M
position
C
Citadel
Ken Griffin · Q1 2026 13F
$3.6M
position

Show all 8 holdersShow fewer holders

FL
FMR LLC
Q1 2026 13F
$421.0M
position
B
BlackRock
Q1 2026 13F
$163.3M
position
JC

Insiders

What insiders are doing

12 trades · 6 mo

Sold$11.6M

Sells (5)

GT
Girao Tiago
Chief Financial Officer · Cluster · Jul 24
$263K
sold
SJ
Stout Jay S
Chief Technology Officer · Cluster · Jul 24
$111K
sold

Checking federal contract awards

Coverage gaps for IMVTNo recent market-voice mention

News

Recent coverage and its overall tone.

News

What the news says

10 articles · 7 days

Coverage leans bearish

1 bullish · 6 neutral · 3 bearish

Tone of tracked coverage

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
NeutralJul 23
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
NeutralJul 23
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
NeutralJul 23
Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed
Leans bearishJul 22
Immunovant, Inc. SEC Filing (Jul 22, 2026)
NeutralJul 22
Immunovant stock trades steady as cash reserves support ongoing autoimmune drug trials
Leans bullishJul 22
Law firm investigates Immunovant officers for possible self-dealing harming shareholders
BearishJul 20
Understanding Momentum Shifts in (IMVT)
NeutralJul 19

JPMorgan Chase

Q1 2026 13F

$2.3M

position

PA

Pande Atul

Dir · Cluster · Jul 24

$60K

sold

VE

Venker Eric

Chief Executive Officer · Jul 6

$119K

sold

SJ

Stout Jay S

Chief Technology Officer · Cluster · Jun 26

$1.5M

sold